New Hope of Kalydeco (VX-770) Makes Headlines and Newscasts Around the Nation
| 2 min read

CNN, CBS News and the Los Angeles Times were among major media outlets that recently featured stories about Kalydeco™ (VX-770), and the promise of this potential CF drug, which is undergoing review for approval by the U.S. Food & Drug Administration.

The news coverage was inspired by the publication last week of data from the Phase 3 trial of Kalydeco in the New England Journal of Medicine, the world's most widely read and influential medical periodical.

Kalydeco was developed by Vertex Pharmaceuticals, Inc., with Cystic Fibrosis Foundation support and research input. If approved, it will be the first drug on the market that targets the underlying cause of CF, rather than just the symptoms of the disease. The drug is for people with the G551D mutation of CF.

Chronicled in the Los Angeles Times is the story of one patient, Lindsay Shipp, who took part in the Kalydeco clinical trial. It wasn't too long ago that Shipp, a 27-year-old singer and dancer, watched her dreams of performing on Broadway fade away.

Since participating in the Kalydeco clinical trial, she has experienced dramatic improvements in her health and is optimist about her future again.

“It's like there are someone else's lungs inside of me," Shipp said in the article. "It's awesome - I feel like I can do anything."

Read the L.A. Times story and other major media coverage here:

Additional Resources

Share this article
About the CF Foundation | CFTR Modulators
Recent news
CF Foundation Establishes Health Equity Awards to Advance Research Toward Optimal Health Outcomes
News | 5 min read
CF Foundation Honors the Legacy of Joe O’Donnell
News | 4 min read
CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 
News | 2 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.